3
Announcements
Trials
Browse
Landscape
Status
Terminated
2
Enrolling by invitation
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
zilucoplan
1
toripalimab
1
somapacitan
1
rozanolixizumab
1
pembrolizumab
1
ibrutinib
1
futibatinib
1
exemestane
1
enzalutamide
1
durvalumab
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Tamoxifen
1
Robotic Surgical Procedures
1
Observation
1
Letrozole
1
Lenalidomide
1
JNJ-64619178
1
JNJ-64264681
1
Inosine Monophosphate
1
Fulvestrant
1
Folfox protocol
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Anastrozole
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
INDUSTRY
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled